[Form 4] Telix Pharmaceuticals Ltd Insider Trading Activity

Rhea-AI Filing Summary

Telix Pharmaceuticals Group Chief Financial Officer Darren Charlton Smith exercised previously granted share rights into ordinary shares. On March 29, 2026, he converted 1,111 share rights into 1,111 ordinary shares at an exercise price of $0.00 per share. These share rights were granted on January 1, 2025 and became vested and exercisable on March 5, 2026. Following the transaction, he directly holds 11,921 ordinary shares of Telix Pharmaceuticals Ltd, and the exercised share rights position has been fully used with no remaining derivative balance reported. No open-market sale occurred in this filing; it reflects a routine compensation-related option exercise that increases his direct share ownership.

Insider Trade Summary

1,111 shares exercised/converted

Mixed 2 txns

Insider Smith Darren Charlton

Role Group Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Share Rights	1,111	$0.00	--
Exercise	Ordinary Shares	1,111	$0.00	--

Holdings After Transaction: Share Rights — 0 shares (Direct); Ordinary Shares — 11,921 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Share rights exercised: 1,111 share rights Ordinary shares acquired: 1,111 shares Shares held after transaction: 11,921 ordinary shares +4 more

7 metrics

Share rights exercised 1,111 share rights Exercised into ordinary shares on March 29, 2026

Ordinary shares acquired 1,111 shares Received upon exercise at $0.00 per share

Shares held after transaction 11,921 ordinary shares Direct ownership following March 29, 2026 exercise

Exercise price $0.00 per share Price for converting share rights into ordinary shares

Grant date of share rights January 1, 2025 Share rights that were later exercised

Vesting date of share rights March 5, 2026 Date rights became vested and exercisable

Original expiration date of share rights March 31, 2028 Expiration for derivative share rights before exercise

Key Terms

Share Rights, derivative security, Ordinary Shares, Group Chief Financial Officer, +1 more

5 terms

Share Rights financial

"The share rights (SRs) were granted on January 1, 2025 and became vested"

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Ordinary Shares financial

"underlying_security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Group Chief Financial Officer financial

"officer_title": "Group Chief Financial Officer""

A group chief financial officer (CFO) is the executive responsible for overseeing a company's overall financial health and strategies across all its divisions or subsidiaries. Think of them as the financial captain of a large organization, guiding decision-making to ensure stability and growth. Investors pay attention to the group CFO because their leadership influences the company’s financial stability and ability to meet its goals.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Darren Charlton

(Last) (First) (Middle)

C/O TELIX PHARMACEUTICALS LTD

55 FLEMINGTON RD

(Street)

NORTH MELBOURNE 3051

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Telix Pharmaceuticals Ltd [ TLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Group Chief Financial Officer

2a. Foreign Trading Symbol
[TLX]

3. Date of Earliest Transaction (Month/Day/Year)
03/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/29/2026		M		1,111	A	$0	11,921	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Rights	$0	03/29/2026		M			1,111	(1)	03/31/2028	Ordinary Shares	1,111	$0	0	D

Explanation of Responses:

1. The share rights (SRs) were granted on January 1, 2025 and became vested and exercisable on March 5, 2026.

Remarks:

	/s/ Oliver Newman, on behalf of Mr. Darren Smith, Group CFO	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)